Significance: Antioxidant and redox signaling (ARS) events are regulated by critical
molecules that modulate antioxidants, reactive oxygen species (ROS) or reactive nitrogen …

Glucagon‐like peptide‐1 (GLP‐1) is an incretin hormone mainly secreted from intestinal L
cells in response to nutrient ingestion. GLP‐1 has beneficial effects for glucose homeostasis …

Summary Background Glucagon-like peptide-1 (GLP-1) analogues reduce hepatic steatosis,
concentrations of liver enzymes, and insulin resistance in murine models of fatty liver …

Aims/hypothesis Liraglutide, a daily injectable glucagon-like peptide-1 receptor (GLP-1r)
agonist, has been shown to reduce liver fat content (LFC) in humans. Data regarding the …

Fatty liver diseases, which are commonly associated with high-fat/calorie diet, heavy alcohol
consumption and/or other metabolic disorder causes, lead to serious medical concerns …

Background & Aims Insulin resistance and lipotoxicity are pathognomonic in non-alcoholic
steatohepatitis (NASH). Glucagon-like peptide-1 (GLP-1) analogues are licensed for type 2 …

Type 2 diabetes (T2D) is a metabolic disease characterized by insulin resistance, β-cell
dysfunction, and elevated hepatic glucose output. Over 350 million people worldwide have …

Abstract BACKGROUND Sirtuins (SIRT1-7) are a family of NAD+-dependent deacetylases
that catalyze post-translational modifications of proteins. Together, they respond to …

The obesity pandemic is accompanied by increased risk of develo** metabolic syndrome
(MetS) and related conditions: non-alcoholic fatty liver disease (NAFLD)/non-alcoholic …

Nonalcoholic fatty liver disease (NAFLD) is prevalent in patients with obesity or type 2
diabetes. Nonalcoholic steatohepatitis (NASH), encompassing steatosis with inflammation …